Let’s start with why it’s needed

Patients with both heart failure (HF) and atrial fibrillation (AF) often face more severe symptoms, more hospital stays, and a higher risk of death than patients with just one of these conditions. A treatment called catheter ablation—which aims to restore a normal heart rhythm—has shown promise in improving heart function and symptoms in small studies. But it’s still not clear whether ablation actually helps patients with both HF and AF live longer or avoid hospital. Until now, trials have been too small, too selective, or have given mixed results, so this important question remains unanswered.

The CRAAFT-HF study is a large trial that will help provide a clear answer. It will include 1,200 patients with HF and AF across the UK and other countries, and compare standard medical treatment with and without catheter ablation. As very few patients with HF currently receive ablation, this research is urgently needed. The goal is to understand not just whether ablation reduces deaths and emergency hospital visits, but also whether it helps patients feel better and live well for longer. The results could shape future guidelines and improve care for hundreds of thousands of patients.